NCT02267603 · OUTCOME

Immune Correlates of the Clinical Activity of Pembrolizumab

Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer · Source last updated 2023-07-05

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Baseline

What was measured

This will include immunohistochemical and gene expression analysis focusing on delineating the immune components and immunologic milieu within the tumor before therapy.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: This will include immunohistochemical and gene expression analysis focusing on delineating the immune components and immunologic milieu within the tumor before therapy.
reporting Status: NOT_POSTED
time Frame: Baseline
title: Immune Correlates of the Clinical Activity of Pembrolizumab
type: OTHER_PRE_SPECIFIED

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice